Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
CAMBRIDGE, Mass., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced today that the company will participate in the 34th Annual J.P. Morgan Healthcare Conference in San Francisco. Chairman of the Board of Directors Sandford D. Smith is scheduled to present on Thursday, January 14, 2016 at 8:00 a.m. PST (11:00 a.m. EST). Mr. Smith will also introduce Aegerion’s newly appointed Chief Executive Officer, Mary Szela.
The presentation will be webcast live and may be accessed for up to 30 days following the conference by visiting the “Investors” section of Aegerion’s website, www.aegerion.com.
About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. For more information about the company, please visit www.aegerion.com.
CONTACT: Aegerion Pharmaceuticals, Inc. Amanda Murphy Associate Director, Investor Relations 857-242-5024
